Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949755 | 1.00 | ADORA1 (0.62) | ADORA1ADORA2AADORA3ADORA2BMEN1 | |
| SCHEMBL7076255 | 1.00 | ADORA1 (0.62) | ADORA1ADORA2AADORA3ADORA2BMEN1 | |
| SCHEMBL5390238 | 1.00 | ADORA1 (0.62) | ADORA1ADORA2AADORA3ADORA2BMEN1 | |
| SCHEMBL4850933 | 0.89 | ADORA3 (0.68) | ADORA1ADORA2AADORA3ADORA2BCYP1A2 | |
| SCHEMBL5380373 | 0.87 | ADORA2A (0.65) | ADORA1ADORA2AADORA3ADORA2BMEN1 | |
| SCHEMBL3952297 | 0.87 | ADORA2A (0.65) | ADORA1ADORA2AADORA3ADORA2BMEN1 | |
| SCHEMBL6259642 | 0.87 | LMNA (0.73) | ADORA1ADORA2AADORA3ADORA2BCYP1A2 | |
| SCHEMBL4801134 | 0.87 | LMNA (0.73) | ADORA1ADORA2AADORA3ADORA2BCYP1A2 | |
| SCHEMBL5389974 | 0.87 | LMNA (0.73) | ADORA1ADORA2AADORA3ADORA2BCYP1A2 | |
| SCHEMBL4805449 | 0.83 | LMNA (0.49) | ADORA1ADORA2AADORA3ADORA2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078232-A1 | Adenosine receptor A3 agonists | CV THERAPEUTICS, INC. | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078232-A1 | Adenosine receptor A3 agonists | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.